CGC vs OGI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CGC and OGI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CGC and OGI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Canopy Growth Corporation is one of Canada's largest cannabis companies, based in Smiths Falls, Ontario. It sells recreational (adult-use) and medical cannabis in Canada, exports medical cannabis to international markets in Europe and Australia, and owns Storz & Bickel, a maker of premium vaporizer devices. Its revenue comes mainly from selling cannabis flower, pre-rolls, vapes, edibles, and beverages under brands like Tweed and Doja, plus device sales. In fiscal 2026 the company completed its acquisition of MTL Cannabis, a move it says makes it Canada's leading medical-cannabis provider by revenue, and reported that its core cannabis business returned to growth after years of contraction.

Full CGC guide

Organigram Global Inc. is a Canadian cannabis company that cultivates, processes, and sells adult-use and medical cannabis products, including dried flower, pre-rolls, vapes, edibles, and a fast-growing lineup of cannabis and hemp-derived beverages. It changed its name from Organigram Holdings to Organigram Global in 2025, keeping the ticker OGI, and trades on both the Nasdaq and the Toronto Stock Exchange (it reports in Canadian dollars). By recreational market share it is Canada's number-one cannabis company, and it has been expanding beyond Canada into international medical markets and the US hemp-derived THC beverage space.

Full OGI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CGC drivers: Core cannabis business back to growth; MTL Cannabis and medical leadership.
• OGI drivers: British American Tobacco partnership; Scale, Motif synergies, and market share.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is that Canopy is still unprofitable in a brutally competitive industry. For OGI, the overarching risk is that cannabis remains federally illegal in the United States, which locks Organigram out of the largest potential market, limits access to US banking and exchanges for the plant-touching business, and caps the sector's valuations.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CGC if you believe its drivers more; OGI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CGC and OGI guides.

CGC. These figures are qualitative and tied to the asOf date; verify live numbers before acting. Because Canopy is unprofitable, standard earnings multiples do not apply, and the stock trades on revenue trajectory, cash runway, and expectations for cannabis reform rather than on profits. Reported financials are also in Canadian dollars, so US-dollar figures depend on exchange rates. Treat any single quarter with caution: cannabis results swing on pricing, one-time charges, and restructuring.

OGI. Figures are approximate, reported in Canadian dollars, drawn from Organigram's fiscal 2026 reporting, and tied to the asOf date; verify live numbers before acting. For a cannabis company, revenue growth, adjusted EBITDA, and cash are more telling than headline net income, which can swing on non-cash fair-value adjustments to biological assets and investments. Cannabis stocks also trade heavily on sector sentiment and regulatory headlines, so traditional earnings multiples are of limited use here.

Headline figures (approximate, Jul 2026): CGC shows revenue trend (fy2026) Modest annual growth (roughly mid-single-digit percent), the first sustained return to growth after years of contraction, growth drivers Double-digit gains in Canadian adult-use, Canadian medical, and international cannabis; device sales (Storz & Bickel) were softer, profitability Still net-loss-making, but fiscal 2026 net loss from continuing operations narrowed roughly by half versus the prior year, balance sheet Shifted to a net-cash position after a January 2026 recapitalization, reducing near-term financing risk; OGI shows gross revenue (q1 fy2026, reported feb 2026) Approximately C$97 million, up roughly 46% year over year (figures in Canadian dollars), net revenue (q1 fy2026) Approximately C$63.5 million, up roughly 49% year over year, adjusted ebitda (q1 fy2026) Approximately C$5.3 million, a sharp improvement (up roughly 273%) year over year, international revenue (q1 fy2026) Approximately C$5 million, up about 51% year over year.

CGC and OGI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CGC and OGI exposure against your real portfolio. It is not an investment adviser.